Testing a diabetes medicine for repaired tetralogy of Fallot
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This study tests a type of diabetes medicine (SGLT2 inhibitor) to see if it can help people who had surgery for tetralogy of Fallot feel better and have stronger heart and lung function. It may be a good fit if you are an adult with repaired tetralogy of Fallot and do not have certain other health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have repaired tetralogy of Fallot (a heart defect fixed with surgery)
- You do not have severe heart failure (ejection fraction under 40%)
- You do not have advanced kidney disease (stage 4 or 5)
- You have not taken an SGLT2 inhibitor (like empagliflozin or dapagliflozin) in the last 6 months
- You are not pregnant or breastfeeding, and have no recent severe infections or diabetes requiring insulin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a registry that follows adults with congenital heart disease who have started taking an SGLT2 inhibitor medication. The goal is to learn how well this treatment works for this group of patients.
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
This trial tests if a drug called dapagliflozin (an SGLT2 inhibitor) can help prevent complications in people with prediabetes when added to lifestyle changes. It aims to see if this approach works better than lifestyle changes alone.
This study tests a medication called dapagliflozin, which is usually for type 2 diabetes, to see if it can be used safely in people with type 1 diabetes. It focuses on preventing a serious side effect called ketoacidosis, where the blood becomes too acidic.
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
Hear when a new Congenital Heart Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.